Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05366855 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
A Phase 3 study, sponsored by Vanda Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 42
- Enrollment target
NCT05366855: Clinical Trial Phase 3 study, sponsored by Vanda Pharmaceuticals.
NCT05366855 is a Phase 3 study that was terminated before completion, run by Vanda Pharmaceuticals. The registered enrollment target is 42 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05366855, a Phase 3 study, was terminated before completion, sponsored by Vanda Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a Phase 3, long term extension study to evaluate the safety and efficacy of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
Interventions
- OTHER Placebo
- OTHER Standard of Care (SOC)
- DRUG Double-blind 200 mg imsidolimab
- DRUG Open-label 200 mg imsidolimab
- DRUG Imsidolimab 750 mg IV/200 mg SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-04-21 |
| Est. Completion | 2024-07-12 |
| Phase | Phase 3 |
Why NCT05366855 stopped before completion
NCT05366855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT05366855 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05366855 about?
NCT05366855 is a clinical study titled "Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP". This is a Phase 3, long term extension study to evaluate the safety and efficacy of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
What is the current status of trial NCT05366855?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 42 participants. The study started on 2022-04-21. Estimated completion is 2024-07-12.
What interventions are being tested in trial NCT05366855?
The interventions under investigation include: Placebo (OTHER), Standard of Care (SOC) (OTHER), Double-blind 200 mg imsidolimab (DRUG), Open-label 200 mg imsidolimab (DRUG), Imsidolimab 750 mg IV/200 mg SC (DRUG).
Who is sponsoring clinical trial NCT05366855?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05366855's enrollment target sits among peer trials
42 1877th of 2000 higher than 124 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI